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A 41-year-old woman was diagnosed with duodenal follicular lymphoma.  She had no other lesions and 
was assigned to a “watch and wait” policy.  Swelling of the inguinal lymph nodes appeared 45 months 
later,  and rituximab monotherapy resulted in complete remission.  However,  follicular lymphoma 
recurred in the stomach,  rectum and mesenteric and external iliac lymph nodes 81 months after the 
therapy.  The patient received rituximab monotherapy again and has remained in complete remission 
in the ﬁfteenth year after the initial diagnosis.  This case suggests the usefulness of rituximab mono-
therapy in the long-term management of intestinal follicular lymphoma.
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ollicular lymphoma is deﬁned as a neoplasm of 
transformed follicle center B cells [1].  
Although most follicular lymphoma cases present with 
nodal involvements,  primary follicular lymphoma 
lesions can arise in the gastrointestinal tract [2-7].  
The number of patients newly diagnosed with primary 
gastrointestinal follicular lymphoma has been increas-
ing in recent years,  as increasing numbers of endosco-
pists and gastroenterologists become familiar with this 
entity.  As a result,  primary gastrointestinal follicular 
lymphoma was listed in the latest version of the World 
Health Organization (WHO) classiﬁcation of lymphoid 
tissues as a distinct variant of systemic follicular 
lymphoma [6].  However,  the standard therapy for 
primary gastrointestinal follicular lymphoma remains 
to be determined.  Moreover,  only a few reports are 
available regarding the long-term prognosis of this 
disease,  particularly that beyond 10 years.
　 Here we describe a patient with primary duodenal 
follicular lymphoma who was treated with single-agent 
rituximab and followed-up for 15 years.  It is notewor-
thy that the disease relapse occurred not in the duode-
num,  but in the stomach and rectum.  This case 
underscores the importance of surveillance of not only 
the duodenum but the entire intestinal tract during the 
follow-up of primary duodenal follicular lymphoma 
cases.
Case Report
　 A 41-year-old woman underwent esophagogas-
troduodenoscopy for screening as a routine medical 
checkup.  Multiple white nodules were detected in the 
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2nd part of the duodenum (Fig.  1A,  B).  Though the 
initial pathological diagnosis of the biopsy specimen 
was extranodal marginal zone lymphoma of mucosa-
associated lymphoid tissue (MALT lymphoma),  
reevaluation with immunostaining results including 
positivity for CD20,  CD10,  and BCL2 led to the 
diagnosis of follicular lymphoma [8] (Fig.  1D-G).  
The pathological grade was 1,  according to the WHO 
classiﬁcation [6].  The patient had no history of gas-
trointestinal or lymphoproliferative diseases.  Physical 
examination revealed no abnormalities,  and there was 
no evidence of hepatosplenomegaly or peripheral 
lymphadenopathy.  Colonoscopy and computed tomog-
raphy (CT) scanning of the neck,  chest,  abdomen and 
pelvis revealed no lymphoma lesions in other parts of 
the body.  The duodenal lesions were also too small to 
detect by CT scanning.  Bone marrow aspirate and 
biopsy were negative for lymphoma inﬁltration.  The 
patient had no symptoms,  and thus she was assigned 
to a “watch and wait” policy.  However,  suspicious 
swelling of the inguinal lymph nodes appeared 45 
months later.  Progression of follicular lymphoma was 
conﬁrmed by pathological evaluation of biopsied sam-
ples of the lymph node.  Treatment with 4 courses of 
rituximab (375mg/m2 intravenous infusion once 
weekly for 4 weeks/course,  every 6 months) resulted 
in the disappearance of the duodenal and inguinal 
lesions.
　 The patient remained in complete remission until an 
esophagogastroduodenoscopy performed 81 months 
after the start of rituximab monotherapy detected a 
10-mm reddish,  ﬂat lesion in the gastric fundus 
(Fig.  2),  despite the fact that the duodenal lesions 
showed no signs of recurrence (Fig.  1C).  
Additionally,  colonoscopy showed small-protruded 
lesions in the rectum,  and biopsy specimens from both 
the gastric and rectal lesions conﬁrmed the involve-
ment of follicular lymphoma (Fig.  3).  Positron emis-
sion tomography scanning demonstrated swelling of the 
mesenteric and right external iliac lymph nodes and 








Fig. 1　 Esophagogastroduodenoscopic and pathological images of the lesion in the duode-
num.  Multiple white nodules were observed in the 2nd part of the duodenum under white-light 
observation (A) and after indigo-carmine contrast spraying (B).  The duodenal lesions disap-
peared after treatment with four courses of rituximab (16 doses) (C).  Inﬁltration of tumor cells 
with lymphoid follicular formation was found in the biopsy specimen (D; hematoxylin and eosin).  
Though the initial pathological diagnosis of the biopsy specimen was MALT lymphoma,  reevalu-
ation with immunostaining results including positivity for CD20 (E).  CD10 (F),  and BCL2 (G) 
led to the diagnosis of follicular lymphoma.  
tracer uptake of ﬂuorodeoxyglucose within these 
lesions (Fig.  4).  These involvements were considered 
to be relapsed follicular lymphoma lesions rather than 
de novo lymphoma lesions,  although clonality testing 
was not done.  Rituximab monotherapy was restarted,  
and the disappearance of the stomach lesion was con-
ﬁrmed by esophagogastroduodenoscopy 5 months after 
the initiation of therapy (Fig.  5A,  B).  The patient 
received another four courses of rituximab mono-
therapy.  The rectal lesion disappeared 14 months 
after the initiation of rituximab therapy,  and the 
treatment was completed 2 years after induction (Fig.  
5C).  No recurrence of follicular lymphoma has been 
detected for 4 years since the completion of the second 
course of rituximab monotherapy.  The patient appears 
to be in complete remission in the ﬁfteenth year since 
being diagnosed with duodenal follicular lymphoma.
Discussion
　 The duodenum is one of the most frequently 






Fig. 2　 Esophagogastroduodenoscopic and pathological images of the stomach lesions.  A 10-mm-size reddish,  ﬂat lesion was detected 
in the gastric fundus under white-light observation (A) and after indigo-carmine contrast spraying (B).  The biopsy specimen conﬁrmed the 
diagnosis of follicular lymphoma (C,  D; hematoxylin and eosin,  C,  D).  Immunohistochemical studies of the biopsy specimen showed that 
lymphoma cells were positive for CD20 (E),  CD10 (F),  and BCL2 (G) and negative for CD3 (H).
Fig. 4　 Positron emission 
tomography scanning images.  
Swelling of the mesenteric 
(arrow) and right external iliac 
lymph nodes (arrowhead) and 
tracer uptake of ﬂuorodeoxy-
glucose within these lesions 
were observed.
aﬀected sites in cases with primary intestinal follicu-
lar lymphoma [2].  The typical endoscopic presenta-
tion of duodenal follicular lymphoma is well known to 
be multiple tiny whitish granules,  as presented in our 
case [7,  9-10].  Historically,  the ﬁrst case of gastro-
intestinal follicular lymphoma was reported in 1997 
[11].  Subsequently,  Yoshino and coworkers summa-
rized their cases in 2000 and indicated increased 
incidence of this disease arising in the duodenum [2].  
Therefore,  it has only been possible to shed light on 
the features of primary intestinal follicular lymphoma 
in the last decade.
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Fig. 5　 Esophagogastroduodenoscopic and colonoscopic images.  After treatment with rituximab every 6 months,  the gastric (A,  B) and 






Fig. 3　 Colonoscopic and pathological images of the rectal lesions. Small,  protruding lesions were shown in the rectum under white-
light observation (A) and after indigo-carmine contrast spraying (B).  The biopsy specimen revealed that the lesion was follicular lymphoma 
(C,  D; hematoxylin and eosin,  C,  D).  Immunohistochemical studies showed that the lymphoma cells were positive for CD20 (E),  CD10 
(F),  and BCL2 (G) and negative for CD3 (H).
　 Generally,  follicular lymphoma of nodal origin is 
characterized by slow-growing lymphadenopathy [6,  
12].  Thus,  because of its indolent nature,  nodal fol-
licular lymphoma patients with limited stage show 
favorable overall survival; 10-year overall survival 
rates after radiation therapy range from 60 to 80ｵ,  
and the median survival is approximately 19 years 
[12-13].  We assume that primary follicular lympho-
mas arising in the gastrointestinal tract have progno-
ses similar to or even better than those of limited-
stage nodal follicular lymphomas,  particularly in cases 
with duodenal involvement [7,  15].  In this context,  
analysis of the prognosis over a long term of 10 years 
or more is considered to be crucial.  However,  the 
long-term clinical course has rarely been reported due 
to the historical background of this disease entity as 
described above.  For example,  although case series 
of gastrointestinal follicular lymphomas have recently 
been reported by several institutions [9,  15-16] as 
well as by us [7],  few studies include cases followed 
up for more than 10 years [17].
　 Besides the detailed depiction of the 15-year clini-
cal course,  our present case has 2 important implica-
tions regarding the management of primary intestinal 
follicular lymphomas.  First,  single-agent rituximab 
caused the lymphoma lesions to regress.  In cases of 
nodal-origin follicular lymphomas,  there are many 
reports on the eﬃcacy of rituximab monotherapy.  
Colombat et al.  [18] noted that 80ｵ of untreated 
follicular lymphoma patients with a low tumor burden 
responded,  and that 48ｵ of the patients analyzed 
achieved complete molecular remission after four infu-
sions of rituximab at 1-week intervals.  In terms of 
long-term prognosis,  40/46 nodal cases treated with 
rituximab monotherapy were followed-up for 84 
months [18].  The median progression-free survival 
was 23.5 months,  and the overall survival rate was 
91.7ｵ.  Though 5/46 patients died due to progres-
sion (n=1),  myelodysplasia (n=1),  diﬀuse large B-cell 
lymphoma (n=1) and solid tumors (n=2),  the majority 
of patients with a low tumor burden were progres-
sion-free as a result of rituximab monotherapy.  
Schmatz et al.  reported that,  in gastrointestinal fol-
licular lymphoma cases,  rituximab monotherapy 
resulted in complete regression (n=4) and stable dis-
ease (n=1) without progression or relapse during the 
median follow-up of 36 months (29-118 months) [9].  
Although a retrospective case series or prospective 
observational study should be conducted to examine 
the usefulness of rituximab monotherapy for gastroin-
testinal follicular lymphomas cases,  these previous 
results indicate that rituximab monotherapy may be a 
therapeutic option for intestinal cases as well as nodal 
cases.  Additionally,  our case suggests that single-
agent rituximab might be useful for treating relapse 
lesions in the intestinal tract.
　 In the present patient,  rituximab was administered 
over an extended period of time for a total of 16 
doses (intravenous infusion once weekly for 4 weeks/
course,  every 6 months) as the ﬁrst-line treatment.  
The same treatment regimen was applied when the 
lymphoma lesions relapsed,  because the progression-
free survival had been long (over 6 years) after the 
initial treatment.  This regimen was reported by 
Hainsworth et al.  in 2002 as the ﬁrst-line therapy for 
indolent non-Hodgkinʼs lymphomas [19].  In their 
report,  the 36 patients with follicular lymphoma or 
small lymphocytic lymphoma who were treated showed 
high overall response (73ｵ) and complete response 
(37ｵ) rates.  The usefulness of maintenance adminis-
tration of rituximab for 2 years has also been reported 
in a phase 3,  randomized controlled trial for patients 
with high-tumor-burden follicular lymphoma [20].  The 
trial study demonstrated that,  although the overall 
survival was not diﬀerent,  progression-free survival 
was superior in patients treated with a 2-year admin-
istration of rituximab after immunochemotherapy 
compared with immunochemotherapy alone.  Though 
there has been no report showing an advantage of 
rituximab administration for such an extended period 
of time (a total of 16 doses) over the usual regimen (a 
total of 4 doses) in follicular lymphoma patients with 
a low tumor burden,  the present case shows the 
potential beneﬁt of this protocol.
　 The second important implication is that the dis-
ease relapse was observed not in the duodenum where 
the lymphoma primarily had arisen,  but in the stomach 
and rectum.  To our knowledge,  no report has 
described such a recurrence in distant gastrointestinal 
parts.  Soubeyran et al.  studied the natural clinical 
course of 26 cases with stage I nodal follicular lym-
phoma who underwent complete resection as an initial 
therapy [21-22].  Of these 26 patients,  exactly half 
(13; 50ｵ) had relapsed during a median follow-up of 
6.3 years; the relapse site was local in 6 cases and 
distant from the resected lesion in 7.  Consequently,  
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we consider that gastrointestinal follicular lymphoma 
patients should be followed up with esophagogas-
troduodenoscopy,  colonoscopy and CT scanning,  
preferably in combination with enteroscopy,  to detect 
the progression or relapse of lymphoma.
　 In summary,  our present case with primary duode-
nal follicular lymphoma received rituximab monother-
apy and was in complete remission in the 15th year 
after the initial presentation,  despite a relapse in the 
stomach and rectum.  This case indicates that ritux-
imab monotherapy can result in long-term disease 
control in gastrointestinal follicular lymphoma 
patients.  Moreover,  periodic surveillance with gas-
troduodenoscopy and colonoscopy may be required 
during the follow-up period.
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